Company / Free Cash Flow
Esperion Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$13.1M
FY2025
5-year range
-$263.8M / -$13.1M
FY2021-FY2025
Trend
+45.4%
vs FY2024
Sector context
#70 of 194
Health Care
What the data says
At -$13M, Esperion Therapeutics, Inc.'s free cash flow ranks #70 of 194 in the Health Care sector. Free Cash Flow has increased for 4 consecutive years, from -$264M in FY2021 to -$13M in FY2025.
Based on SEC 10-K filings.
-$13M in FY2025.
Improved from -$135M to -$13M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#70 of 194 in Health CareTop 36% of 194This company -$13.1M Sector average $470.6M
▼
-102.8% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s free cash flow has grown for 4 consecutive years.
- In FY2025, free cash flow increased 45.4% year-over-year.
- Ranks #70 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$13.1M | +45.4% |
| FY2024 | -$24.0M | +82.3% |
| FY2023 | -$135.5M | +22.5% |
| FY2022 | -$174.8M | +33.7% |
| FY2021 | -$263.8M | -206.6% |
| FY2020 | -$86.0M | -20.7% |
| FY2019 | -$71.3M | +52.1% |
| FY2018 | -$148.8M | -13.3% |
| FY2017 | -$131.3M | -174.6% |
| FY2016 | -$47.8M | -24.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026